{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:03:46Z","timestamp":1780347826047,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.7759\/cureus.110070","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T20:36:38Z","timestamp":1780346198000},"source":"Crossref","is-referenced-by-count":0,"title":["Burned-Out Autoimmune Disease: A Multicenter Case Series Revealing a Distinct Clinical Phase and Its Implications for Immunosuppressive Therapy"],"prefix":"10.7759","author":[{"given":"Ibrahim","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Alkadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Abdelaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Wissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung SA","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, et al.. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021, 73:1366-83. 10.1002\/art.41773","journal-title":"Arthritis Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis A","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, et al.. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019, 78:736-45. 10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","unstructured":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021, 100.S1-S276. 10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little MA","year":"2010","unstructured":"Little MA, Nightingale P, Verburgh CA, et al.. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010, 69:1036-43. 10.1136\/ard.2009.109389","journal-title":"Ann Rheum Dis"},{"key":"ref5","article-title":"Association between renal involvement and relapse in ANCA-associated vasculitis","volume":"20","author":"Lionaki S","year":"2009","unstructured":"Lionaki S, Hogan SL, Falk RJ, et al.. Association between renal involvement and relapse in ANCA-associated vasculitis. J Am Soc Nephrol. 2009, 20:453-60.","journal-title":"J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro S","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al.. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023, 82:19-34. 10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde D","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, et al.. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017, 76:978-91. 10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum 2020","volume":"76","author":"Parikh SV","year":"2020","unstructured":"Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020, 76:265-81. 10.1053\/j.ajkd.2019.10.017","journal-title":"Am J Kidney Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015","volume":"68","author":"Tektonidou MG","year":"2016","unstructured":"Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015. Arthritis Rheumatol. 2016, 68:1432-41. 10.1002\/art.39594","journal-title":"Arthritis Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching AR","year":"2020","unstructured":"Kitching AR, Anders HJ, Basu N, et al.. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020, 6:71. 10.1038\/s41572-020-0204-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05610611","article-title":"Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease","volume":"7","author":"McGregor JG","year":"2012","unstructured":"McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012, 7:240-7. 10.2215\/CJN.05610611","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper J","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017, 390:73-84. 10.1016\/S0140-6736(16)31591-4","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/498195-burned-out-autoimmune-disease-a-multicenter-case-series-revealing-a-distinct-clinical-phase-and-its-implications-for-immunosuppressive-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T20:36:39Z","timestamp":1780346199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/498195-burned-out-autoimmune-disease-a-multicenter-case-series-revealing-a-distinct-clinical-phase-and-its-implications-for-immunosuppressive-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.110070","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}